Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 15;3(1):35.
doi: 10.1186/s44158-023-00114-6.

Remdesivir administration for SARS-CoV-2 pneumonia in ICU and non-ICU patients: outcome and posttreatment differences - the Italian Military Hospital experience

Antonio Sabba  1 , Giancarlo Pontoni  2 , Maria Santangelo  3 , Nadir Rachedi  3 , Maurizio D'Ercole  3 , Bernardino Marseglia  2 , Marcella Fusaro  3 , Elena Giovanna Bignami  4 , Costantino Fontana  3
Affiliations

Remdesivir administration for SARS-CoV-2 pneumonia in ICU and non-ICU patients: outcome and posttreatment differences - the Italian Military Hospital experience

Antonio Sabba et al. J Anesth Analg Crit Care. .

Abstract

Background: Four-hundred forty-nine patients affected by Covid-19 were hospitalized at the Rome Military Hospital between March 2020 and July 2022. Depending on the severity of the disease, they were assigned either to the Functional Health Emergency Unit - if suffering from interstitial pneumonia with a clinical manifestation of dyspnea associated with peripheral oxygen saturation < 92%, and oxygen atmospheric pressure therapy - or to the intensive care unit - if the blood gas-lytic index P/F (ratio between partial pressure of arterial O2 and inspired fraction of O2) was below 150. This prospective observation and monocentric study aim to verify the outcome (healing/death) of early use of remdesivir in pneumonia patients.

Results: The results highlight the importance of the adoption of remdesivir in the initial stages of infection to prevent the systemic spread and viral multiplication and, in the subsequent phase, a cytokine storm resulting in acute respiratory failure and multiorgan failure. The use of the drug in the most advanced stages of the disease is not associated with a real impact on patient outcomes. Therefore, there is a statistically significant correspondence between the early use of remdesivir in the treatment of SARS-CoV-2 disease - in addition to guidelines therapies - and a favorable clinical outcome.

Conclusions: This work shows therapeutic efficacy in the first 5 days of intravenous administration of remdesivir, following the loading dose. It is also necessary to underline the different behaviors of the drug when administered late in patients undergoing mechanical ventilation, compared to those who only needed low-flow oxygen therapy, whose share of recovery - decidedly relevant - reaches statistical significance.

Keywords: Covid-19; Intensive care; Remdesivir.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Outcome and therapy UFES
Fig. 2
Fig. 2
Outcome therapy ICU
See this image and copyright information in PMC

References

    1. Silva Francisco R, Benittes F, Lamarca AP, et al. Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co- infection events by two different lineages in Rio Grande do Sul, Brazil. medRxiv 2021, posted 26 January. 10.1101/2021.01.21.21249764 - PMC - PubMed
    1. Callaway E. Fast-spreading COVID variant can elude immune responses. Nature News 21 January 2021. https://www.nature.com/articles/d41586-021-00121-z - PubMed
    1. Starr TN, Greaney AJ, Hilton SK, et al. Deep mutational scanning of SARS- CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020;182(5):1295–1310.e20. doi: 10.1016/j.cell.2020.08.012. - DOI - PMC - PubMed
    1. Tillett RL, Sevinsky JR, Hartley PD, et al. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2021;21(1):52–58. doi: 10.1016/S1473-3099(20)30764-7. - DOI - PMC - PubMed
    1. Davies NG, Barnard RC, Jarvis CI et al. Estimated transmissibility and severity of novel SARSCoV- 2 variant of concern 202012/01 in England. medRxiv 2020, published 26 December. 10.1101/2020.12.24.20248822

LinkOut - more resources